10:12 AM EDT, 08/07/2024 (MT Newswires) -- Ocular Therapeutix ( OCUL ) shares rose 4.3% in recent Wednesday trading after the biopharmaceutical company posted higher Q2 net revenue from a year earlier that also topped analysts' forecasts.

The company reported a Q2 net loss of $0.26 per diluted share, unchanged from a year earlier.

Analysts polled by Capital IQ expected a loss of $0.22.

Net revenue for the quarter ended June 30 was $16.4 million, up from $15.2 million a year earlier.

Analysts surveyed by Capital IQ expected $15.9 million.

Price: 8.23, Change: +0.34, Percent Change: +4.31